UBS Upgrades Helicos BioSciences (HLCS) to Neutral
More News related to HLCS
- Helicos Ships Genetic Analysis System To Stanford University
- Helicos BioSciences to Present at UBS Global Life Sciences Conference on September 25, 2008
- Helicos BioSciences to Present at Thomas Weisel Partners Healthcare Conference 2008 September 3, 2008
- Helicos Announces Personnel Changes Aimed at Accelerating R&D
- Helicos BioSciences (HLCS) Names Lombardi as New CEO
More News related to Upgrades
- Examine the Global Wind Power Industry with This Essential 2008 Report
- BioSolar Anticipates Federal Clean Energy Tax Package to Benefit Solar Industry
- Hilton HHonors Offers Members International Auction: HHonors Members Throughout the World Can Now Bid Points for the Ultimate Martell Experience
- Cloud Computing Pioneer Chooses Isilon IQ
- Former Cables to Go/Lastar Inc. Employee's Move to Form American Consumer Cables Pays Off
UBS upgrades Helicos BioSciences (Nasdaq: HLCS) from Sell to Neutral.
Helicos BioSciences Corporation is a life sciences company developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
